Ultragenyx Pharmaceutical (NASDAQ:RARE) reported second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio, while the company prepared for potential regulatory decisions on two gene therapies and a late-stage data readout in Angelman syndrome.
Chief Exe
Rigel Pharmaceuticals (NASDAQ:RIGL) reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August.
The company generated $67 million in U.S. net product sales during the quarter
Red Rock Resorts (NASDAQ:RRR) reported second-quarter results that declined from a year earlier but remained among the strongest second-quarter performances in the company’s history, as its Las Vegas operations navigated renovation and construction-related disruption at several properties.
Las Vega
Solid Power (NASDAQ:SLDP) reported a second-quarter net loss of $23.8 million, or $0.11 per share, as the solid-state battery materials company continued to invest in electrolyte development, customer programs and a continuous-production pilot line.
Revenue for the second quarter was negative $300,
ePlus (NASDAQ:PLUS) reported fiscal first-quarter 2027 results that reflected modest revenue growth against a difficult prior-year comparison, while bookings and open orders increased substantially amid demand for artificial intelligence infrastructure, security, cloud and managed services.
Chief E
PROCEPT BioRobotics (NASDAQ:PRCT) reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. Management said newer HYDROS Robotic System accounts continued to show stronger utilization, support
Qualys (NASDAQ:QLYS) reported second-quarter 2026 revenue growth of 11% to $182.2 million and raised its full-year outlook, citing improved upsell execution, growing channel contribution and customer interest in its enterprise risk-management platform and automated remediation capabilities.
Chief E
Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet.
Total second-quarter revenue rose 6% fro
Paylocity (NASDAQ:PCTY) reported fourth-quarter fiscal 2026 recurring revenue growth of 12.4% and total revenue growth of 11%, as the human capital management software provider highlighted product expansion, artificial intelligence initiatives and continued client growth.
For the fiscal year ended
Precigen (NASDAQ:PGEN) reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy’s August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.
PAPZIMEOS revenue total
Amazon's cloud dominance and fortress balance sheet clash with Carnival's cyclical recovery and cheaper valuation; each offers a distinct risk-reward profile.
Match Group (NASDAQ:MTCH) reported second-quarter revenue of $853 million, down 1% from a year earlier, while adjusted EBITDA rose 14% to $331 million. The company said progress at Tinder, including improved engagement trends and a broader product roadmap, supported its confidence in the business de
Onespan (NASDAQ:OSPN) reported second-quarter 2026 revenue of $60.5 million, up 1% from a year earlier, as growth in subscription revenue and digital agreements partly offset lower hardware and perpetual-maintenance revenue. The company raised its full-year revenue and adjusted EBITDA outlook, citin
Lattice Semiconductor (NASDAQ:LSCC) reported record second-quarter revenue as demand from AI data centers, traditional cloud infrastructure and industrial applications lifted results, while the company also completed its acquisition of firmware and infrastructure manageability provider AMI.
Revenue
Mattel (NASDAQ:MAT) reported second-quarter 2026 net sales growth of 10% on a reported basis and 9% in constant currency, supported by double-digit growth in North America, vehicles, games, action figures and digital gaming. The company reiterated its full-year outlook, while noting that higher adve
Marqeta (NASDAQ:MQ) reported second-quarter 2026 results that included 32% growth in total processing volume, 17% growth in net revenue and gross profit, and its second consecutive quarter of GAAP profitability. Management also outlined product expansion initiatives in stablecoin-backed cards, non-c
